Sunday, February 27, 2022

New desensitization treatment for highly sensitized kidney transplant patients

Hansa Biopharma AB, “Hansa” today announced that its first-in-class treatment Idefirix® (imlifidase) has been granted early access post marketing authorization (Autorisation d’accès précoce) in France by French HAS (Haute Autorité de Santé) for use in the desensitization of highly sensitized adult patients prior to kidney transplant, in accordance with the patient population specified in the Marketing Authorization received from the European Medicines Agency (EMA).1,2 The aim of early access programs in France is to accelerate access to innovative medicines before […] - eTurboNews | Travel News

No comments:

Post a Comment